美国HIV相关隐球菌脑膜炎AMBITION方案卫生经济学分析
该回顾性经济学评价在美国一家大型公立学术医院比较了AMBITION方案与指南依从治疗用于HIV相关隐球菌脑膜炎的成本。34例AMBITION方案患者相较26例对照患者,为医院净节省399 704美元(每例11 756美元);按全国晚期HIV支付方构成建模后医院仍净节省,支付方角度亦显示节省。
要点
- AMBITION方案较指南依从治疗每例为医院净节省11 756美元。
- 按全国支付方构成建模后医院仍净节省,但幅度因商业保险支付损失而缩小。
- 支付方角度建模显示各支付方构成下均节省。
核心结论
- 在该经济学评价中,AMBITION方案与医院和支付方的费用节省均相关,支持在美国采用该方案治疗隐球菌脑膜炎。
研究设计与样本
- 回顾性经济学评价,分析美国一家大型公立学术医院2020年8月至2024年7月HIV相关隐球菌脑膜炎患者的成本,AMBITION方案34例、对照26例。
- 对照为指南依从治疗,即脂质类两性霉素(3-5 mg/kg/日)联合氟胞嘧啶(100 mg/kg/日)至少14天。
- AMBITION方案为单剂脂质体两性霉素联合2周氟康唑和氟胞嘧啶。
主要发现
- AMBITION方案治疗34例相较26例对照患者,为医院净节省399 704美元,即每例11 756美元,按节省的可变成本减去损失的收入计算。
- 所涉及的各类保险类型均出现费用节省,但无商业保险患者。
- 按全国晚期HIV患者支付方构成建模后,医院仍净节省,但幅度较小,原因是损失了商业保险支付。
关键数值与推荐
- 净节省计算方式为节省的可变成本减去损失的收入。
- 指南依从方案为脂质类两性霉素3-5 mg/kg/日联合氟胞嘧啶100 mg/kg/日,至少14天。
- AMBITION方案为单剂脂质体两性霉素联合2周氟康唑和氟胞嘧啶。
临床怎么用
- 对HIV相关隐球菌脑膜炎,可考虑采用AMBITION方案以降低医院与支付方成本,同时需结合本地支付方构成评估节省幅度。
局限性
- 为单中心回顾性经济学评价,样本量较小(34例对26例)。
- 研究期间无商业保险患者,支付方构成需借助全国晚期HIV数据建模外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current guideline-compliant management of cryptococcal meningitis (CM), comprised of lipid-based amphotericin (3-5 mg/kg/day) and flucytosine (100 mg/kg/day) for a minimum of 14 days, is associated with significant costs to both the hospital and insurance payor. Recently published studies have found comparable patient outcomes with the cheaper and better tolerated AMBITION protocol (single-dose liposomal amphotericin with 2 weeks of fluconazole and flucytosine). METHODS: This retrospective, economic evaluation analyzed costs associated with the AMBITION protocol versus guideline-compliant care for patients with human immunodeficiency virus (HIV)-associated CM at a large, academic, public US hospital between August 2020 and July 2024. RESULTS: Treatment of 34 patients with the AMBITION protocol compared to 26 control patients net saved the hospital $399 704 ($11 756 per patient), calculated as variable costs saved minus revenue lost. Cost savings were experienced across all insurance types encountered; however, there were no patients with commercial insurance. In order to accurately model patients who develop CM, we obtained data on the nationwide payor mix for patients with advanced HIV, which still showed net hospital savings, though of smaller magnitude due to lost commercial insurance payments. From an insurance payor perspective, modeling demonstrated cost savings across payor mixes. CONCLUSIONS: In this economic evaluation study, the AMBITION protocol was associated with both hospital and payor savings. These findings provide further support for adoption of the AMBITION protocol for treatment of CM in the United States.
引用
- Clark DC, Banerjee J, Baden R, et al. Health Economic Analysis of the AMBITION Protocol for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis in the United States. Clin Infect Dis. 2026. PMID: 42752855. doi:10.1093/cid/ciag485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。